title: Free-water and BOLD imaging changes in Parkinson's disease patients chronically treated with a MAO-B inhibitor.
abstract: Rasagiline is a monoamine oxidase type B inhibitor that possesses no amphetamine-like properties, and provides symptomatic relief in early and late stages of Parkinson's disease (PD). Data in animal models of PD suggest that chronic administration of rasagiline is associated with structural changes in the substantia nigra, and raise the question whether the structure and function of the basal ganglia could be different in PD patients treated chronically with rasagiline as compared with PD patients not treated with rasagiline. Here, we performed a retrospective cross-sectional magnetic resonance imaging (MRI) study at 3 T that investigated nigrostriatal function and structure in PD patients who had taken rasagiline before testing (∼8 months), PD who had not taken rasagiline before testing, and age-matched controls. The two PD groups were selected a priori to not differ significantly in age, sex, disease duration, severity of symptoms, cognitive status, and total levodopa equivalent daily dose of medication. We evaluated percent signal change in the posterior putamen during force production using functional MRI, free-water in the posterior substantia nigra using diffusion MRI, and performance on a bimanual coordination task using a pegboard test. All patients were tested after overnight withdrawal from antiparkinsonian medication. The rasagiline group had greater percent signal change in the posterior putamen, less free-water in the posterior substantia nigra, and better performance on the coordination task than the group not taking rasagiline. These findings point to a possible chronic effect of rasagiline on the structure and function of the basal ganglia in PD. Hum Brain Mapp 37:2894-2903, 2016. © 2016 Wiley Periodicals, Inc.
authors.affiliation: Department of Applied Physiology and Kinesiology, University of Florida, Gainesville, Florida.
authors.forename: Roxana G
authors.initials: RG
authors.lastname: Burciu
authors.affiliation: Department of Applied Physiology and Kinesiology, University of Florida, Gainesville, Florida.
authors.forename: Edward
authors.initials: E
authors.lastname: Ofori
authors.affiliation: Department of Applied Physiology and Kinesiology, University of Florida, Gainesville, Florida.
authors.forename: Priyank
authors.initials: P
authors.lastname: Shukla
authors.affiliation: Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.|Department of and Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
authors.forename: Ofer
authors.initials: O
authors.lastname: Pasternak
authors.affiliation: Department of Applied Physiology and Kinesiology, University of Florida, Gainesville, Florida.
authors.forename: Jae Woo
authors.initials: JW
authors.lastname: Chung
authors.affiliation: Department of Neurology, University of Florida, Gainesville, Florida.|Center for Movement Disorders and Neurorestoration, College of Medicine, University of Florida, University of Florida, Gainesville, Florida.
authors.forename: Nikolaus R
authors.initials: NR
authors.lastname: McFarland
authors.affiliation: Department of Neurology, University of Florida, Gainesville, Florida.|Center for Movement Disorders and Neurorestoration, College of Medicine, University of Florida, University of Florida, Gainesville, Florida.|Department of Neurosurgery, University of Florida, Gainesville, Florida.
authors.forename: Michael S
authors.initials: MS
authors.lastname: Okun
authors.affiliation: Department of Applied Physiology and Kinesiology, University of Florida, Gainesville, Florida.|Department of Neurology, University of Florida, Gainesville, Florida.|Department of Biomedical Engineering, University of Florida, Gainesville, Florida.
authors.forename: David E
authors.initials: DE
authors.lastname: Vaillancourt
mesh_terms: D000368:Aged; D001931:Brain Mapping; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D007189:Indans / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D012189:Retrospective Studies; D013378:Substantia Nigra / Q000187:drug effects*; D014867:Water / Q000032:analysis
chemical_list: D007189:Indans; D008996:Monoamine Oxidase Inhibitors; C031967:rasagiline; D014867:Water
keywords: Parkinson's disease; free-water diffusion MRI; nigrostriatal regions; rasagiline; task-based fMRI